Human IL-6

Name: Human IL-6
Availability: InStock

Human IL-6

Recombinant human IL-6 (interleukin 6) can promote differentiation of B and T cells (Th17) and can stimulate proliferation of hematopoietic progenitor cells or hybridoma cells. The pleiotropic cytokine has crucial function, such as in the regulation of immune and inflammatory responses or hematopoiesis. Recombinant human IL-6 is specifically developed for use in cell culture, differentiation studies, and functional assays.

Product data and images for Human IL-6

Figures

Figure 1

**Human IL-6 activity assay.**
The biological activity of Human IL-6, premium grade was determined by proliferation assay using B9 hybridoma cells.

Figure 1

Human IL-6 activity assay.

The biological activity of Human IL-6, premium grade was determined by proliferation assay using B9 hybridoma cells.

Figure 2

**SDS-PAGE of Human IL-6, premium grade**
under reduced (R) and non-reduced (NR) conditions.

Figure 2

SDS-PAGE of Human IL-6, premium grade

under reduced (R) and non-reduced (NR) conditions.

Figure 3

Mass spectrometry analysis (ESI-MS) of Human IL-6, premium grade. The peak corresponds to the calculated molecular mass of 20812 Da.

Figure 3

Mass spectrometry analysis (ESI-MS) of Human IL-6, premium grade. The peak corresponds to the calculated molecular mass of 20812 Da.

Specifications for Human IL-6

Overview

Recombinant human IL-6 (interleukin 6) can promote differentiation of B and T cells (Th17) and can stimulate proliferation of hematopoietic progenitor cells or hybridoma cells. The pleiotropic cytokine has crucial function, such as in the regulation of immune and inflammatory responses or hematopoiesis. Recombinant human IL-6 is specifically developed for use in cell culture, differentiation studies, and functional assays.

Applications

Human IL-6 can be used for a variety of applications, including:

Induction of colony formation from hematopoietic progenitor cells in semi-solid medium.
Replacement of feeder cells in the preparation of murine and human hybridomas.
In vitro differentiation of T_H17 cells.

Detailed product information

Background information

IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine, which regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions. It induces, for instance, the terminal maturation of activated B cells into antibody-secreting plasma cells and acts in synergy with IL-3 to support the proliferation of hematopoietic stem cells. IL-6 is produced by many cell types, such as monocytes, fibroblasts, endothelial cells, T cells, etc. Disturbed IL-6 production has been associated with pathological processes including inflammatory autoimmune diseases, such as rheumatoid arthritis and cancer.

Biological activity

Proliferation of B9 hybridoma cells (NIBSC 89/548)
research grade: ≥ 2×
10
⁷
IU/mg
premium grade: ≥ 5×
10
⁷
IU/mg

(Typical specific activity: ≥ 1.3×
10
⁸
IU/mg
)
We measure the biological activity of each batch of MACS Premium-Grade Cytokines and state the results in the Certificate of Analysis (CoA). Based on the lot-specific activity, exact doses of active cytokine can be applied to cell culture experiments. This allows for reproducible cell culture conditions without the need for time-consuming lot-to-lot testing.

Quality description

Research-grade

cytokines are suitable for a wide variety of cell culture applications. They are sterile-filtered prior to lyophilization. Generally, endotoxin levels are <0.1 ng/μg (<1 EU/μg), and purities are >95%. The biological activity is tested in appropriate bioassays.

Premium-grade

cytokines offer the convenience of high and well-defined biological activities and allow exact unit dosing for demanding applications. The biological activity is determined after lyophilization and reconstitution, and normalized to WHO/NIBSC standards whenever available. In general, endotoxin levels are <0.01 ng/μg (<0.1 EU/μg), and purities are >97%. Lot-specific activities are stated in the Certificate of Analysis (www. miltenyibiotec.com/certificates).

Resources for Human IL-6

Documents and Protocols

Background information

Premium-grade cytokine benefits

App notes/customer reports

How to switch to optimal activity-based cytokine dosing

Certificates

Please follow this

link

to search for Certificates of Analysis (CoA) by lot number.

References for Human IL-6

Publications

Hoppenbrouwers, T. et al. (2020) Specific Polyunsaturated Fatty Acids Can Modulate in vitro Human moDC2s and Subsequent Th2 Cytokine Release. Front Immunol 11: 748
Meurer, T. et al. (2018) Dissecting Genetic Control of HLA-DPB1 Expression and Its Relation to Structural Mismatch Models in Hematopoietic Stem Cell Transplantation. Front Immunol 9: 2236
Tregnago, C. et al. (2021) NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML. Cancers (Basel) 13(14): 3457
Buks, R. et al. (2021) ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis. Int J Mol Sci 22(7): 3530
Moras, M. et al. (2020) Downregulation of Mitochondrial TSPO Inhibits Mitophagy and Reduces Enucleation during Human Terminal Erythropoiesis. Int J Mol Sci 21(23): 9066
Goepfert, K. et al. (2019) Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing. Front Oncol 9: 425
Bosch, N. C. et al. (2019) NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells. Ther Adv Med Oncol 11: 1758835919891622
Xu, Y. et al. (2019) Ferumoxytol Attenuates the Function of MDSCs to Ameliorate LPS-Induced Immunosuppression in Sepsis. Nanoscale Res Lett 14(1): 379
Gaines-Das, R. E. and Poole, S. (1993) The international standard for interleukin-6. Evaluation in an international collaborative study. J. Immunol. Methods 160: 147-153
Brault, J. et al. (2014)
Optimized generation of functional neutrophils and macrophages from patient-specific induced pluripotent stem cells:
ex vivo
models of X
⁰
-linked, AR22
⁰
- and AR47
⁰
- chronic granulomatous diseases.
Biores Open Access 3(6): 311-326
Dighe, N. et al. (2014) Long-term reproducible expression in human fetal liver hematopoietic stem cells with a UCOE-based lentiviral vector. PLoS One 9(8): e104805
Ghirelli, C. et al. (2010) Systematic cytokine receptor profiling reveals GM-CSF as a novel TLR-independent activator of human plasmacytoid predendritic cells. Blood 115(24): 5037-5040
Kaebisch R. et al. (2014) Helicobacter pylori cytotoxin-associated gene A impairs human dendritic cell maturation and function through IL-10-mediated activation of STAT3. J Immunol 192: 316-323
Laurenti, E. et al. (2015) CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell 16(3): 302-313
Steinleitner, K. et al. (2012) EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages. Anticancer Res. 32(11): 4883-4889
Wright, C. et al. (2012) Detection of multiple autoantibodies in patients with ankylosing spondylitis using nucleic acid programmable protein arrays. Mol. Cell. Proteomics 11(2): M9.00384

Data and images